Lucid Capital initiated coverage of Neuphoria Therapeutics (NEUP) with a Buy rating and $81 price target The company is developing BNC210 to treat social anxiety disorder episodically, the analyst tells investors in a research note. The firm says that with no agent approved for the acute treatment of anxiety attacks in a social situation, BNC210 offers a “best- and first-in-class” profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP: